{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:38:55Z","timestamp":1792784335211,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003606","name":"Korea Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003606","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korean Government"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.neuropharm.2017.08.015","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T10:45:14Z","timestamp":1502534714000},"page":"396-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":169,"special_numbering":"C","title":["Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease"],"prefix":"10.1016","volume":"125","author":[{"given":"Nikita","family":"Katila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Bhurtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Shadfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Srivastav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabita","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil-Saeng","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.08.015_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2008.10.103","article-title":"Okadaic acid protects human neuroblastoma SH-SY5Y cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis","volume":"449","author":"Ahn","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2015.12.012","article-title":"Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL\/6J mice","volume":"301","author":"Allard","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/sj.cdd.4401662","article-title":"Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways","volume":"12","author":"Almeida","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2049-3002-2-12","article-title":"Metformin directly acts on mitochondria to alter cellular bioenergetics","volume":"2","author":"Andrzejewski","year":"2014","journal-title":"Cancer Metab."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-015-0067-y","article-title":"Novel (Hetero) arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease","volume":"11","author":"Baranyi","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib6","doi-asserted-by":"crossref","first-page":"e0159381","DOI":"10.1371\/journal.pone.0159381","article-title":"Metformin prevents nigrostriatal dopamine degeneration independent of AMPK activation in dopamine neurons","volume":"11","author":"Bayliss","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib7","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1523\/JNEUROSCI.4373-15.2016","article-title":"Ghrelin-AMPK signaling mediates the neuroprotective effects of calorie restriction in Parkinson's disease","volume":"36","author":"Bayliss","year":"2016","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20140620","article-title":"Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria","volume":"462","author":"Bridges","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.nbd.2009.01.016","article-title":"A\u00a0highly reproducible rotenone model of Parkinson's disease","volume":"34","author":"Cannon","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nature07813","article-title":"AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity","volume":"458","author":"Canto","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nn1443","article-title":"\u03b1-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease","volume":"8","author":"Chen","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib12","doi-asserted-by":"crossref","first-page":"e5482","DOI":"10.1371\/journal.pone.0005482","article-title":"Striatal neuroinflammation promotes Parkinsonism in rats","volume":"4","author":"Choi","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2013.11.002","article-title":"The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in\u00a0vitro","volume":"63","author":"Dulovic","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.expneurol.2004.01.023","article-title":"Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone","volume":"187","author":"Fleming","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib16","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrendo.2015.85","article-title":"Therapy: metformin takes a new route to clinical efficacy","volume":"11","author":"Foretz","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cbi.2010.06.003","article-title":"Molecular mechanisms of pesticide-induced neurotoxicity: relevance to Parkinson's disease","volume":"188","author":"Franco","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"[alpha]-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.tpj.6500360","article-title":"Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease","volume":"6","author":"Fumagalli","year":"2006","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pneurobio.2013.10.004","article-title":"Autophagy and apoptosis dysfunction in neurodegenerative disorders","volume":"112","author":"Ghavami","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0006-8993(02)02505-2","article-title":"Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in\u00a0vitro","volume":"941","author":"Goggi","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib22","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1523\/JNEUROSCI.20-15-05775.2000","article-title":"BDNF protects the neonatal brain from hypoxic-ischemic injury in\u00a0vivo via the ERK pathway","volume":"20","author":"Han","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/350230a0","article-title":"BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra","volume":"350","author":"Hyman","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib24","series-title":"Decrease in Plasma Levels of \u03b1-Synuclein Is Evident in Patients with Parkinson's Disease after Elimination of Heterophilic Antibody Interference","author":"Ishii","year":"2015"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib25","first-page":"42","article-title":"Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways","volume":"6","author":"Islam","year":"2009","journal-title":"Curr. Res."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.taap.2016.03.004","article-title":"Metformin, besides exhibiting strong in\u00a0vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system","volume":"298","author":"Ismaiel","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuint.2016.12.002","article-title":"Enhanced dopaminergic neurotoxicity mediated by MPTP in IL-32beta transgenic mice","volume":"102","author":"Jung","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib28","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib29","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1038\/cddis.2013.447","article-title":"(ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease","volume":"4","author":"Kim","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nn1175","article-title":"Localized striatal delivery of GDNF as a treatment for Parkinson disease","volume":"7","author":"Kirik","year":"2004","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib31","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1523\/JNEUROSCI.6513-10.2011","article-title":"Enhanced phosphatase activity attenuates \u03b1-synucleinopathy in a mouse model","volume":"31","author":"Lee","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib32","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1523\/JNEUROSCI.6513-10.2011","article-title":"Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model","volume":"31","author":"Lee","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13311-012-0165-2","article-title":"Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease","volume":"10","author":"Lee","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib34","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-014-0177-4","article-title":"Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion","volume":"11","author":"Liu","year":"2014","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw047","article-title":"Metformin prevents dopaminergic neuron death in MPTP\/P-induced mouse model of Parkinson's disease via autophagy and mitochondrial ROS clearance","volume":"19","author":"Lu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/NEN.0b013e318180f0bd","article-title":"Pathologic modifications of \u03b1-synuclein in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated squirrel monkeys","volume":"67","author":"McCormack","year":"2008","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib38","doi-asserted-by":"crossref","first-page":"14311","DOI":"10.1523\/JNEUROSCI.0499-12.2012","article-title":"AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease","volume":"32","author":"Ng","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.brainres.2016.05.013","article-title":"Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice","volume":"1644","author":"Oliveira","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib40","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.4161\/auto.25878","article-title":"Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases","volume":"9","author":"Osellame","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.bbrc.2009.07.164","article-title":"Metformin suppresses glucose-6-phosphatase expression by a complex I inhibition and AMPK activation-independent mechanism","volume":"388","author":"Ota","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib42","doi-asserted-by":"crossref","first-page":"e1209","DOI":"10.1038\/cddis.2014.175","article-title":"Metformin lowers Ser-129 phosphorylated \u03b1-synuclein levels via mTOR-dependent protein phosphatase 2A activation","volume":"5","author":"P\u00e9rez-Revuelta","year":"2014","journal-title":"Cell death Dis."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib43","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/acn3.337","article-title":"Dysregulation of protein phosphatase 2A in Parkinson disease and dementia with lewy bodies","volume":"3","author":"Park","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib44","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuroscience.2014.07.046","article-title":"Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice","volume":"277","author":"Patil","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bbrc.2016.07.068","article-title":"Quercetin ameliorates ischemia\/reperfusion-induced cognitive deficits by inhibiting ASK1\/JNK3\/caspase-3 by enhancing the Akt signaling pathway","volume":"478","author":"Pei","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib46","doi-asserted-by":"crossref","first-page":"e1209","DOI":"10.1038\/cddis.2014.175","article-title":"Metformin lowers Ser-129 phosphorylated alpha-synuclein levels via mTOR-dependent protein phosphatase 2A activation","volume":"5","author":"Perez-Revuelta","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12640-016-9633-5","article-title":"Metformin prevented dopaminergic neurotoxicity induced by 3,4-methylenedioxymethamphetamine administration","volume":"30","author":"Porceddu","year":"2016","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12868-015-0192-0","article-title":"Exogenous \u03b1-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes","volume":"16","author":"Rannikko","year":"2015","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib49","series-title":"Direct Visualization of Alpha-synuclein Oligomers Reveals Previously Undetected Pathology in Parkinson's Disease Brain","author":"Roberts","year":"2015"},{"key":"10.1016\/j.neuropharm.2017.08.015_bib50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40478-016-0357-9","article-title":"Novel antibodies to phosphorylated \u03b1-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes","volume":"4","author":"Rutherford","year":"2016","journal-title":"Acta neuropathol. Commun."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib51","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1074\/jbc.M115.705095","article-title":"Effects of Serine 129 phosphorylation on \u03b1-synuclein aggregation, membrane association, and internalization","volume":"291","author":"Samuel","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12640-009-9061-x","article-title":"Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease","volume":"16","author":"Schintu","year":"2009","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib53","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-016-0342-0","article-title":"Neuroprotective effects of antidepressants via upregulation of neurotrophic factors in the MPTP model of Parkinson's disease","author":"Shadfar","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib54","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.55782\/ane-2015-2012","article-title":"Role of the unfolded protein response in the pathogenesis of Parkinson's disease","volume":"75","author":"Varma","year":"2015","journal-title":"Acta Neurobiol. Exp."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib56","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","article-title":"Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort","volume":"18","author":"Wahlqvist","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biocel.2016.03.007","article-title":"The novel mechanism of rotenone-induced \u03b1-synuclein phosphorylation via reduced protein phosphatase 2A activity","volume":"75","author":"Wang","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib58","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.08.015_bib59","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1017\/S1461145714000315","article-title":"TL-2 attenuates beta-amyloid induced neuronal apoptosis through the AKT\/GSK-3beta\/beta-catenin pathway","volume":"17","author":"Zhu","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T02:49:52Z","timestamp":1719370192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817303829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":59,"alternative-id":["S0028390817303829"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.015","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin lowers \u03b1-synuclein phosphorylation and upregulates neurotrophic factor in the MPTP mouse model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}